2024
73. Preliminary Efficacy Findings for a Placebo Controlled Randomized Clinical Trial of a Novel Executive Working Memory Training Intervention for Adolescents With ADHD
Sullivan A, Anderson J, Beatty M, Choi J, Jaccard J, Pearlson G, Stevens M. 73. Preliminary Efficacy Findings for a Placebo Controlled Randomized Clinical Trial of a Novel Executive Working Memory Training Intervention for Adolescents With ADHD. Biological Psychiatry 2024, 95: s129. DOI: 10.1016/j.biopsych.2024.02.308.Peer-Reviewed Original Research
2021
Tau‐Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease
Das S, Lyu X, Duong M, Xie L, McCollum L, Flores R, DiCalogero M, Irwin D, Dickerson B, Nasrallah I, Yushkevich P, Wolk D, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Shaw L, Liu E, Montine T, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Jiminez G, Harvey D, Donohue M, Bernstein M, Fox N, Thompson P, Schuff N, DeCArli C, Borowski B, Gunter J, Senjem M, Vemuri P, Jones D, Kantarci K, Ward C, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Landau S, Cairns N, Householder E, Reinwald L, Lee V, Korecka M, Figurski M, Crawford K, Neu S, Foroud T, Potkin S, Shen L, Kelley F, Kim S, Nho K, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Carter R, Dolen S, Schneider L, Pawluczyk S, Beccera M, Teodoro L, Spann B, Brewer J, Vanderswag H, Fleisher A, Heidebrink J, Lord J, Petersen R, Mason S, Albers C, Knopman D, Johnson K, Doody R, Meyer J, Chowdhury M, Rountree S, Dang M, Stern Y, Honig L, Bell K, Ances B, Morris J, Carroll M, Leon S, Householder E, Mintun M, Schneider S, Oliver A, Marson D, Griffith R, Clark D, Geld‐Macher D, Brockington J, Roberson E, Grossman H, Mitsis E, Toledo‐Morrell L, Shah R, Duara R, Varon D, Greig M, Roberts P, Albert M, Onyike C, D'Agostino D, Kielb S, Galvin J, Pogorelec D, Cerbone B, Michel C, Rusinek H, Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Wong T, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Sinha P, Oates E, Conrad G, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Ortiz C, Womack K, Mathers D, Quiceno M, Arrastia R, King R, Weiner M, Martin Cook K, DeVous M, Levey A, Lah J, Cellar J, Bums J, Anderson H, Swerdlow R, Apostolova L, Tingus K, Woo E, Silverman D, Lu P, Bartzokis G, Graff Radford N, Parfitt F, Kendall T, Johnson H, Farlow M, Hake A, Matthews B, Herring S, Hunt C, Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Kathleen Johnson N, Brigid Reynolds N, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Sirrel S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Allard J, Lerner A, Ogrocki P, Hudson L, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Adeli A, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Santulli R, Kitzmiller T, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Spicer K, Bachman D, Finger E, Pasternak S, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Boles Ponto L, Shim H, Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Raj B. Tau‐Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Annals Of Neurology 2021, 90: 751-762. PMID: 34617306, PMCID: PMC8841129, DOI: 10.1002/ana.26233.Peer-Reviewed Original ResearchConceptsData-driven subgroupsAlzheimer's diseaseLow atrophyCortical thicknessBrain regionsWhite matter hyperintensity lesionsModulatory factorsAmyloid-positive individualsSubsequent cognitive impairmentLevels of tauGray matter regionsAnn NeurolDownstream neurodegenerationHyperintensity lesionsTau neurofibrillaryTau burdenClinical trialsCognitive impairmentMatter regionsDiseaseMultiple underlying factorsNeurodegenerationAtrophyCohortSUVR
2020
Chapter 10 Medical marijuana and clinical trials
Pearlson G. Chapter 10 Medical marijuana and clinical trials. 2020, 243-260. DOI: 10.1016/b978-0-12-818174-4.00010-0.Peer-Reviewed Original Research
2009
Subregional neuroanatomical change as a biomarker for Alzheimer's disease
Holland D, Brewer J, Hagler D, Fennema-Notestine C, Dale A, Weiner M, Thal L, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Gamst A, Potter W, Montine T, Anders D, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Shaw L, Lee V, Korecka M, Crawford K, Neu S, Harvey D, Kornak J, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Vorobik R, Quinn J, Schneider L, Pawluczyk S, Spann B, Fleisher A, Vanderswag H, Heidebrink J, Lord J, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Mintun M, Schneider S, Marson D, Griffith R, Badger B, Grossman H, Tang C, Stern J, deToledo-Morrell L, Shah R, Bach J, Duara R, Isaacson R, Strauman S, Albert M, Pedroso J, Toroney J, Rusinek H, de Leon M, De Santi S, Doraiswamy P, Petrella J, Aiello M, Clark C, Pham C, Nunez J, Smith C, Given C, Hardy P, DeKosky S, Oakley M, Simpson D, Ismail M, Porsteinsson A, McCallum C, Cramer S, Mulnard R, McAdams-Ortiz C, Diaz-Arrastia R, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Laubinger M, Bartzokis G, Silverman D, Lu P, Fletcher R, Parfitt F, Johnson H, Farlow M, Herring S, Hake A, van Dyck C, MacAvoy M, Bifano L, Chertkow H, Bergman H, Hosein C, Black S, Graham S, Caldwell C, Feldman H, Assaly M, Hsiung G, Kertesz A, Rogers J, Trost D, Bernick C, Gitelman D, Johnson N, Mesulam M, Sadowsky C, Villena T, Mesner S, Aisen P, Johnson K, Behan K, Sperling R, Rentz D, Johnson K, Rosen A, Tinklenberg J, Ashford W, Sabbagh M, Connor D, Obradov S, Killiany R, Norbash A, Obisesan T, Jayam-Trouth A, Wang P, Auchus A, Huang J, Friedland R, DeCarli C, Fletcher E, Carmichael O, Kittur S, Mirje S, Johnson S, Borrie M, Lee T, Asthana S, Carlsson C, Potkin S, Highum D, Preda A, Nguyen D, Tariot P, Hendin B, Scharre D, Kataki M, Beversdorf D, Zimmerman E, Celmins D, Brown A, Gandy S, Marenberg M, Rovner B, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Pare N, Williamson J, Sink K, Potter H, Raj B, Giordano A, Ott B, Wu C, Cohen R, Wilks K, Safirstein B. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proceedings Of The National Academy Of Sciences Of The United States Of America 2009, 106: 20954-20959. PMID: 19996185, PMCID: PMC2791580, DOI: 10.1073/pnas.0906053106.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentAlzheimer's diseaseClinical trialsOutcome measuresCerebral volume changesDisease-modifying effectsCerebral structural changesDisease-modifying agentsSerial MRI scansTemporal lobe cortical regionsSensitive outcome measuresDisease-related changesBrain atrophyNeuroprotective effectsAD pathologyHealthy controlsSubregional atrophyCortical changesEarly diagnosisNeuroanatomical changesCortical thicknessNormal subjectsMRI scansVentricular volumeClinical practice